Compare GoPro Inc (GPRO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Regeneron Pharmaceuticals Inc — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while Regeneron Pharmaceuticals Inc trades at $677.52 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 570.8× GoPro Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | REGN | |
|---|---|---|
Market Cap | $122.03M | $69.66B |
Sector | Technology | Health |
52-Week High | $2.88 | $812.27 |
52-Week Low | $0.64 | $542.52 |
Enterprise Value | $169.98M | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6732, down 3.53% on the day, reflecting persistent financial stress with a net income margin of -20.7% and negative cash flow. The company is undergoing a strategic review for potential sale or merger, announced May 11, 2026, after receiving inbound interest. Technical indicators are bearish, with moving averages signaling continued downward pressure, while recent product launches like the MISSION 1 series aim to revive growth amid declining revenues.
The outlook hinges on the strategic review outcome; a successful sale could provide shareholder value, but ongoing losses and high burn rate pose significant risks. Investors face binary event-driven speculation, with analyst consensus mixed and substantial downside if restructuring fails.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
